首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1604159

全球急性偏頭痛治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Acute Migraine Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年11月01日 | 出版商:

Value Market Research | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球急性偏頭痛治療市場需求預計將從 2023 年的 33.6 億美元達到近 124.6 億美元的市場規模，2024-2032 年研究期間複合年成長率為 15.69%。

偏頭痛是一種反覆發作的神經系統疾病，會導致中度至劇烈頭痛，通常伴隨與自主神經系統相關的症狀。急性偏頭痛治療是控制偏頭痛症狀的過程。急性偏頭痛治療的主要目標是盡快停止偏頭痛並減輕相關症狀。有多種藥物可用於此目的，包括非處方藥 (OTC) 和處方藥。

市場動態

偏頭痛（一種慢性神經系統疾病）的盛行率不斷上升，推動了急性偏頭痛治療市場的發展。此外，隨著越來越多的人尋求偏頭痛治療，人們越來越意識到偏頭痛是一種合法的健康狀況，這也推動了市場的發展。偏頭痛有效治療方法的不斷增加預計將推動急性偏頭痛治療市場的成長。對更個人化的治療方案的需求不斷成長，也推動了新的、更有效的偏頭痛治療方法的發展。然而，高昂的治療成本可能會阻礙市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球急性偏頭痛治療市場的每個細分市場進行了包容性評估。急性偏頭痛治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

急性偏頭痛治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

依藥物類型

曲普坦類
CGRP拮抗劑
非類固醇抗發炎藥
BETA-腎上腺素阻斷劑
麥角生物鹼
其他

依給藥途徑

口服
注射
其他

按配銷通路

醫院藥房
零售藥局
網路藥局

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的急性偏頭痛治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。急性偏頭痛治療市場的主要參與者包括梯瓦製藥、羅氏有限公司、強生公司、安進公司、阿斯特捷利康公司、輝瑞公司、默克公司、諾華公司、艾爾建公司、禮來公司、BioDelivery Sciences國際公司，艾伯維。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：急性偏頭痛治療公司的競爭格局

急性偏頭痛治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Teva Pharmaceutical

公司概況
公司收入
產品
最新動態

Hoffmann-La Roche Ltd.

公司概況
公司收入
產品
最新動態

Johnson & Johnson

公司概況
公司收入
產品
最新動態

Amgen

公司概況
公司收入
產品
最新動態

AstraZeneca

公司概況
公司收入
產品
最新動態

Pfizer Inc.

公司概況
公司收入
產品
最新動態

Merck & Co.

公司概況
公司收入
產品
最新動態

Novartis AG

公司概況
公司收入
產品
最新動態

Allergan Plc

公司概況
公司收入
產品
最新動態

Eli Lilly And Company

公司概況
公司收入
產品
最新動態

BioDelivery Sciences International Inc.

公司概況
公司收入
產品
最新動態

AbbVie

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112110233

The global demand for Acute Migraine Treatment Market is presumed to reach the market size of nearly USD 12.46 Billion by 2032 from USD 3.36 Billion in 2023 with a CAGR of 15.69% under the study period 2024-2032.

Migraine is a recurring neurological condition that causes moderate to intense headaches, often accompanied by symptoms related to the autonomic nervous system. Acute migraine treatment is the process of managing the symptoms of a migraine headache. The primary goal of acute migraine treatment is to stop the migraine headache as soon as possible and to alleviate the associated symptoms. There are several medications that can be used for this purpose, including over-the-counter (OTC) medications and prescription medications.

MARKET DYNAMICS

The increasing prevalence of migraines, a chronic neurological disorder, drives the market for acute migraine treatment. Moreover, the growing awareness of migraines as a legitimate health condition is also driving the market as more people seek treatment for them. The growing availability of effective treatments for migraines is expected to boost the acute migraine treatment market growth. The development of new and more effective migraine treatments is also driven by the increasing demand for more personalized treatment options. However, the high cost of treatment may impede the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Acute Migraine Treatment. The growth and trends of Acute Migraine Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Acute Migraine Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Triptans
CGRP Antagonist
NSAID Drugs
Beta-adrenergic Blockers
Ergot Alkaloids
Others

By Route of Administration

Oral
Injection
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Acute Migraine Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acute Migraine Treatment market include Teva Pharmaceutical, Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen, AstraZeneca, Pfizer Inc., Merck & Co., Novartis AG, Allergan Plc, Eli Lilly And Company, BioDelivery Sciences International Inc., AbbVie. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ACUTE MIGRAINE TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ACUTE MIGRAINE TREATMENT MARKET ANALYSIS BY DRUG TYPE

5.1. Overview By Drug Type
5.2. Historical and Forecast Data Analysis By Drug Type
5.3. Triptans Historic and Forecast Sales By Regions
5.4. CGRP Antagonist Historic and Forecast Sales By Regions
5.5. NSAID Drugs Historic and Forecast Sales By Regions
5.6. Beta-adrenergic Blockers Historic and Forecast Sales By Regions
5.7. Ergot Alkaloids Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL ACUTE MIGRAINE TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Oral Historic and Forecast Sales By Regions
6.4. Injection Historic and Forecast Sales By Regions
6.5. Others Historic and Forecast Sales By Regions

7. GLOBAL ACUTE MIGRAINE TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data Analysis By Distribution Channel
7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
7.4. Retail Pharmacies Historic and Forecast Sales By Regions
7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL ACUTE MIGRAINE TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ACUTE MIGRAINE TREATMENT COMPANIES

9.1. Acute Migraine Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF ACUTE MIGRAINE TREATMENT INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Teva Pharmaceutical
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Hoffmann-La Roche Ltd.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Johnson & Johnson
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Amgen
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. AstraZeneca
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Pfizer Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Merck & Co.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Novartis AG
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Allergan Plc
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Eli Lilly And Company
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. BioDelivery Sciences International Inc.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. AbbVie
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments